NeurodegenerationConfirmed
EU Approved Cenrifki for a Difficult-to-Treat Form of Progressive MS
Sanofi’s Cenrifki/tolebrutinib was approved in the EU for secondary progressive multiple sclerosis without recent relapses, where disability can worsen even without flare-ups.
Why now
The approval targets disability progression in a form of MS where obvious relapses may have stopped.
- Overclaim risk
- medium
- Primary source
- Company
- Published
- Jun 24, 2026
Read brief ->